pharmaphorum

JUNE 8, 2023

Standalone Sandoz eyes $3bn in new product sales by 2028 Phil.Taylor Thu, 08/06/2023 - 07:57 Bookmark this

82

82

European Pharmaceutical Review

DECEMBER 1, 2022

According to GlobalData’s recent report , a total of five marketed messenger RNA (mRNA) non-vaccine products by 2028 will generate over $2 billion, generated by the approval of pipeline agents. billion during 2028.

Vaccines 93

Vaccines Immunization 93

Pharmaceutical Technology

MARCH 30, 2023

The breakthrough drug is predicted to be a blockbuster, generating total forecast sales of $12.9bn between 2023 and 2028. Leqembi is forecast to generate total sales of $12.9bn worldwide between 2023 and 2028. The forecast total sales of $12.9bn by 2028 underscores the significant impact Leqembi is expected to have on the market.

FDA 59

FDA Compounding 59

Pharmaceutical Technology

MARCH 30, 2023

The breakthrough drug is predicted to be a blockbuster, generating total forecast sales of $12.9bn between 2023 and 2028. Leqembi is forecast to generate total sales of $12.9bn worldwide between 2023 and 2028. The forecast total sales of $12.9bn by 2028 underscores the significant impact Leqembi is expected to have on the market.

FDA 52

FDA Compounding 52

Pharmacy Times

JANUARY 22, 2024

The IQVIA Global Use of Medicines report for 2024 predicts that loss of brand exclusivity will negatively impact global market growth.

145

145

Fierce Pharma

APRIL 20, 2023

Amgen nabs appeals win against Otezla generics, blocking Sandoz and Zydus copycats until 2028 zbecker Thu, 04/20/2023 - 10:19

52

52

Drug Topics

JANUARY 19, 2024

According to IQVIA's most recent Global Use of Medicine report, losses for originator products are projected to rise by over $80 billion over the next 5 years due to market introductions of new biosimilar and generic drugs.

98

98

Fierce Pharma

APRIL 23, 2024

The orphan drug sector has long been clearing growth in the larger pharmaceutical market with booming sales. | The orphan drug sector has long been clearing growth in the larger pharmaceutical market with booming sales.

82

82

Fierce Pharma

JANUARY 8, 2024

investors may still get the heebie-jeebies when thinking about Keytruda’s patent cliff in 2028, but the company’s CEO Rob Davis now thinks “it’s just another year.” | While some Merck & Co. While some Merck & Co.

Vaccines 126

Vaccines 126

Fierce Pharma

OCTOBER 31, 2023

As several new JAK inhibitors threaten Incyte’s bread-and-butter Jakafi in myelofibrosis, the company is busy advancing new regimens ahead of the drug’s 2028 patent cliff. |

120

120

STAT

MARCH 25, 2024

With the lease on its two-building campus on Fan Pier set to expire in 2028, the company is reevaluating its real estate options — and considering leaving its prominent headquarters for another spot in the neighborhood. Now, Vertex may be on the move again. Continue to STAT+ to read the full story…

107

107

European Pharmaceutical Review

MARCH 20, 2024

million by 2028. percent between 2022-2028, the research found. Based on the research, the US LIMS market is predicted to value $1 billion by 2028. According to a report by Arizton, the Europe laboratory information management system (LIMS) market is expected to reach $912.47 The market is growing at a CAGR of 10.16

94

94

Fierce Pharma

SEPTEMBER 27, 2023

Viatris just notched a win on its quest to reach $1 billion in eye care sales by 2028. | The FDA on Wednesday approved Viatris and Ocuphire’s Ryzumvi, also known as phentolamine ophthalmic solution, to treat pharmacologically-induced mydriasis, or dilation of the pupils. The partners plan to make Ryzumvi available in the U.S.

FDA 113

FDA 113

Fierce Pharma

FEBRUARY 8, 2024

Editor-in-Chief Ayla Ellison engages in a conversation with Fierce Pharma Marketing Senior Editor Ben Adams about the drugs likely to launch this year with the most significant sales potential by 2028.

75

75

European Pharmaceutical Review

DECEMBER 4, 2023

billion by 2028, growing at a CAGR of 6.8 percent between 2023 to 2028. Moreover, the non-toxic nature of organic chemicals is expected to drive the organic chemicals sectors, ultimately boosting the pharmaceutical excipient market in the forecast period (2023 to 2028).

Pharmaceutical Companies 92

Pharmaceutical Companies Pharmaceutical Companies 92

STAT

JANUARY 8, 2024

That could come as soon as 2028. The bolt-on deal comes as Merck’s top brass searches for ways to bolster the company’s revenue after it loses exclusivity on Keytruda, long the world’s most lucrative cancer drug.

Immunization 119

Immunization 119

Pharmaceutical Commerce

JANUARY 18, 2024

The predicted value is largely driven by manufacturers' prioritization of brand protection.

52

52

Pharmaceutical Technology

JANUARY 15, 2024

MSD’s blockbuster immunotherapy, set to lose patent protection in 2028, secures third FDA approval in cervical cancer.

FDA 59

FDA 59

PharmExec

JULY 18, 2023

Pharma giant to serve as Team USA’s partner in prescription medicine and health equity.

52

52

Pharmaceutical Commerce

SEPTEMBER 25, 2023

This would signify an 8.3% CAGR over the next five years.

52

52

Drug Store News

APRIL 24, 2023

The Appeals Court affirmed the validity of the patent expiring in 2028.

96

96

Pharmaceutical Technology

JANUARY 9, 2024

Set to lose Keytuda patent protection in 2028, MSD is shoring up its oncology portfolio with immunotherapies.

52

52

Pharmacy Times

AUGUST 18, 2022

Study results show a compound annual growth rate of 5.2% billion in revenue in 2021.

Compounding 65

Compounding 65

STAT

SEPTEMBER 28, 2023

The split will take a few years to play out — Dana-Farber and Brigham and Women’s have a contract into 2028 — but has shaken patients and physicians. Anne Klibanski, chief executive of Brigham and Women’s parent organization, Mass General Brigham, placed the blame on Dana-Farber executives.

Hospitals 132

Hospitals 132

Pharmaceutical Technology

JANUARY 30, 2023

These are forecast to generate $264 billion in sales between 2021 and 2028. The forecast across the seven years between 2022 and 2028 saw an average decline of 7%, resulting in a $10 billion drop in the total forecast sales between 2021 and 2028.

Vaccines 52

Vaccines 52

European Pharmaceutical Review

APRIL 15, 2024

The new investment in the Holly Springs facility will “add 8 x 20,000 L mammalian cell culture bioreactors by 2028, to the already planned 8 x 20,000 L for bulk drug substance as part of the initial investment”.

84

84

STAT

JANUARY 25, 2023

The data is a setback for Merck, which has been working to expand use of Keytruda, which has powered its growth for years but will lose exclusivity in 2028. The drug was being tested in combination with androgen deprivation therapy and Xtandi in patients with hormone-sensitive prostate cancer that has spread to other parts of the body.

98

98

European Pharmaceutical Review

NOVEMBER 24, 2023

These activities are expected to be completed incrementally between 2026 to 2028, the company stated. While the current production facility in Chartres, France, employ around 1,600 people, once the new multi-product facilities are in operation, over 500 new jobs will be created to manage continuous production activities.

Packaging 96

Packaging 96

European Pharmaceutical Review

MARCH 14, 2024

billion by 2028, based on data from Evaluate Pharma. Prior to this new facility expansion, SK bioscience highlighted that in 2021, L HOUSE was the first domestic vaccine manufacturing facility to achieve EU-GMP certification from the European Medicines Agency (EMA).

Vaccines 85

Vaccines 85

European Pharmaceutical Review

DECEMBER 19, 2023

The workplan, which runs until 2028, will help the European medicines regulatory network (EMRN) embrace the opportunities of AI for personal productivity, automating processes and systems, increasing insights into data and supporting more robust decision-making to benefit public and animal health.

Packaging 93

Packaging Documentation 93

European Pharmaceutical Review

OCTOBER 16, 2023

The ADC market is expected to grow at a compound annual growth rate (CAGR) of 20 percent between 2023 and 2028, the contract development and manufacturing organisation (CDMO) highlighted. Enhancing manufacturing capabilities The bioconjugates market is currently valued at $33 billion according to research by Lonza.

Compounding 96

Compounding 96

Pharmaceutical Technology

JANUARY 25, 2023

Despite this, Spikevax vaccine market share is expected to decline from 30% in 2022 to just 16% by the end of 2028. The therapeutic is expected to be a strong entrant in late 2023, with forecast sales of $2.5bn in 2028. One such therapeutic is PBI-0451, which is currently under development by Pardes Biosciences.

Vaccines 59

Vaccines 59

pharmaphorum

APRIL 20, 2021

billion by 2028. billion in sales in 2028. Analyst Philippa Salter of GlobalData recently predicted that Kesimpta’s convenience will make it a sought-after option for RMS patients, driving global sales to $3.3 While it requires a clinic visit, Ocrevus only has to be administered twice a year.

Hospitals 111

Hospitals Documentation 111

PharmaShots

MAY 2, 2023

The US FDA was granted the expanded conditional approval authority in the Animal Drug User Fee Act of 2018 with the program planned to sunset in 2028 The efficacy of molidustat oral suspension had been established based on the results of a study conducted in 2 phases in 23 cats aged 4-17yrs.

FDA 45

FDA Vaccines 45

Pharmaceutical Technology

MAY 16, 2023

This growth is expected to continue, with a 62% growth in annual consensus sales forecast from 2023 to 2028, fuelled by the company’s semaglutide portfolio, according to GlobalData’s report, ‘Looking ahead to 2023 – the future of pharma’. Novo Nordisk reported an 18.2%

Vaccines 52

Vaccines FDA 52

European Pharmaceutical Review

JUNE 28, 2023

The treatment is expected to launch in 2028 in the US, EU, and Japan. Data from the ROSE 2 trials suggests that obicetrapib in combination with ezetimibe has the potential to be used in patients who are unable to achieve sufficient LDL-cholesterol lowering with other available lipid-lowering medications,” Dr Mohammad commented.

81

81

PharmaShots

MAY 19, 2023

in quarterly installments during 2024 along with royalties from 2025 to 2028 based on net revenues in the US from Iluvien & Yutiq. Shots: EyePoint to receive $75M up front, $7.5M EyePoint will transfer & assign to Alimera certain assets & certain contracts with third parties related to Yutiq incl.

40

40